Urologic Surgeon, Assistant Professor, Division of Urology, Department of Surgery, University of Alberta
Dr. Fairey received his MD at the University of Alberta in 2006 and completed his residency in Urologic Surgery at the University of Alberta and fellowship training in Urologic Oncology at the University of Southern California/Norris Comprehensive Cancer Center. Dr. Fairey’s main areas of expertise include radical surgical procedures for bladder, prostate, and kidney cancers as well as reconstructive surgery of the lower urinary tract following radical cystectomy or pelvic exenteration. He has a special interest in function-sparing procedures (including advanced reconstructive techniques that re-create the natural urination pathway after bladder removal – continent urinary diversion) to optimize quality of life after surgery. Dr. Fairey is actively involved in clinical and translational research studies in patients with bladder, prostate, and kidney cancers.
Relevant Publications
1. Bachir BG, Aprikian A, Fradet Y, Chin J, Izawa J, Rendon R, Estey E, Fairey AS, Cagiannos I, Lacombe L, Lattouf J, Bell D, Saad F, Drachenberg D, Kassouf W. Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal heath care system. Canadian Urological Association Journal 2013;7(11-12): E667-672.
2. Ploussard G, Shariat SF, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatte T, Boorjian SA, Lotan Y, Rhogmann F, Fairey AS, Fradet Y, Black PC, Rendon R, Izawa J, Kassouf W. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. European Urology 2013 In Press.
3. Fairey AS, Jacobsen NE, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf J-B, Saad F, Drachenberg D, Cagiannos I, Lacombe L, Fradet Y, Kassouf W. Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. European Urology 2013 In Press.
4. Fairey AS, Daneshmand S, Skinner EC, Schuckman A, Cai J, Lieskovsky G. Long-term outcomes of radical prostatectomy for pT3bN0M0 prostate cancer in the prostate-specific antigen era. Urologic Oncology: Seminars and Original Investigations 2013 In Press.
5. Fairey AS, Daneshmand S, Wang L, Schuckman A, Djaladat H, Cai J, Miranda G, Skinner EC. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy. Urologic Oncology: Seminars and Original Investigations 2013
6. Yafi FA, Tanguay S, Rendon R, Jacobsen NE, Fairey AS, Izawa J, Kapoor A, Black P, Lacombe L, Chin J, So A, Lattouf J-B, Bell D, Fradet Y, Saad F, Matsumoto E, Drachenberg D, Cagiannos I, Kassouf W. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urologic Oncology: Seminars and Original Investigations 2013 Epub ahead of print.
7. Williams AK, Kassouf W, Chin J, Rendon R, Jacobsen NE, Fairey AS, Kapoor A, Black P, Lacombe L, Tanguay S, So A, Lattouf J-B, Bell D, Fradet Y, Saad F, Matsumoto E, Drachenberg D, Cagiannos I, Izawa JI. Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 2013 Epub ahead of print.
8. Metcalfe M, Estey E, Jacobsen NE, Voaklander D, Fairey AS. Association between urinary diversion and quality of life after radical cystectomy for bladder cancer. Canadian Journal of Urology 2013;20(1):6626-6631.
9. Metcalfe M, Kassouf W, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Lattouf J-B, Saad F, Lacombe L, Fradet Y, Fairey AS, Jacobsen NE, Drachenberg D, Cagiannos I, So A, Black P. Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. Canadian Urological Association Journal 2012;6(6):455-462.
10. Goh AC, Gill IS, Lee DJ, Abreu A, Fairey AS, Leslie S, Berger AK, Daneshmand S, Sotelo R, Gill K, Xie HW, Aron M, Desai MM. Robot-assisted intracorporeal orthotopic ileal neobladder: replicating open surgical principles. European Urology 2012;62(5):891-901.
11. Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin RP, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC. Neoadjuvant chemotherapy with Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Doxorubicin/Cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California. Urologic Oncology: Seminars and Original Investigations 2012 Epub ahead of print.
12. Fairey AS, Kassouf W, Estey EP, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf J-B, Saad F, Drachenberg D, Cagiannos I, Lacombe L, Fradet Y, Jacobsen NE. Comparison of oncologic outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. British Journal of Urology International 2012 Epub ahead of print.
13. Sandhu GS, Aprikian A, Chin J, Fradet Y, Izawa J, Estey E, Fairey AS, Rendon R, Cagiannos I, Lacombe L, Lattouf J, Bell D, Kassouf W, Drachenberg D. Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience. Canadian Urological Association Journal 2012;6(3):E116-E120.
14. Kotb AF, Kovac E, Kassouf W, Chin J, Fradet Y, Izawa J, Estey E, Fairey AS, Rendon R, Cagiannos I, Lacombe L, Lattouf J, Bell D, Drachenberg D, Aprikian A. Radical cystectomy for clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcomes? World Journal of Urology 2012 Epub ahead of print.
15. Dorin RP, Lieskovsky G, Fairey AS, Cai J, Daneshmand S. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era. Urologic Oncology: Seminars and Original Investigations 2012 Epub ahead of print.
16. Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey AS, Cagiannos I, Lacombe L, Lattouf J-B, Bell D, Saad F, Drachenberg D, Kassouf W. Surveillance guidelines based on recurrence patterns following radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. British Journal of Urology International 2012;110(9):1317-1323.
17. Mason RJ, Kassouf W, Bell DG, Lacombe L, Kapoor A, Jacobsen NE, Fairey AS, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf J-B, Saad F, Matsumoto E, Drachenberg D, Cagiannos I, Fradet Y, Rendon RA. The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience. Urology 2012;79(4):840-845.
18. Power E, Kassouf W, Bell D, Aprikian A, Fradet Y, Lacombe L, Chin J, Izawa J, Estey E, Fairey AS, Cagiannos I, Lattouf J-B, Drachenberg D, Rendon R. Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort. Canadian Urological Association Journal 2012;6(6):E217-223.
19. Fairey AS, Kassouf W, Aprikian A, Fradet Y, Lacombe L, Chin J, Izawa J, Cagiannos I, Lattouf J, Rendon R, Bell D, Drachenberg D, Estey E. Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network database. Urologic Oncology: Seminars and Original Investigations 2012;30(6):825-832.
20. Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, Fairey AS, Rendon R, Cagiannos I, Lacombe L, Lattouf J-B, Bell D, Drachenberg D, Kassouf W. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. British Journal of Urology International 2011;108(4):539-545.
21. Chalasani V, Izawa J, Chin J, Aprikian A, Fradet Y, Estey E, Fairey AS, Rendon R, Cagiannos I, Lacombe L, Lattouf J, Bell D, Drachenberg D, Kassouf W. Outcome of 304 clinical T1G3 bladder cancer patients treated with radical cystectomy: the Canadian Bladder Cancer Network experience. Canadian Urological Association Journal 2011;5:83-87.
22. Miles B, Fairey AS, Eliasziw M, Estey E, Venner P, Finch D, Trpkov K, Eigl B. Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. Canadian Urological Association Journal 2010;4(4):262-266.
23. Fairey AS, Jacobsen NE, Chetner M, Metcalfe JB, Moore RB, Todd G, Mador D, Rourke K, Venner P, Voaklander D, Estey E. Associations between comorbidity and overall survival and bladder cancer-specific survival after radical cystectomy: results from the Alberta Urology Institute radical cystectomy database. The Journal of Urology 2009;182:85-93.
24. Fairey AS, Chetner M, Metcalfe JB, Moore RB, Todd G, Rourke K, Voaklander D, Estey E. Associations among age, comorbidity and clinical outcomes after radical cystectomy: results from the Alberta Urology Institute Radical cystectomy database. The Journal of Urology 2008;180:128-134.